Company research
OMEROS CORP
CIK 1285819Updated Sep 29, 2026
SecurityOMER · NASDAQ · equity
OMER price & chart
Loading TradingView…
NASDAQ:OMER on TradingView ↗About the company
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros’ long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in clinical development for treatment of paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros’ lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of novel cellular and molecular immuno-oncology programs.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER ↗
Recent filings
4 filing
144 filing
144 filing
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Show 5 more recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01
Other Events
Items 8.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 325,632,000Source | 277,079,000Source | 378,269,000Source | 590,969,000Source |
| Property, Plant and Equipment, NetUSD | 1,768,000Source | 2,678,000Source | 1,950,000Source | 1,492,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 9,660,000Source | 3,400,000Source | 7,105,000Source | 11,009,000Source |
| Assets, CurrentUSD | 215,667,000Source | 134,120,000Source | 217,898,000Source | 443,236,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,595,000Source | 7,166,000Source | 8,581,000Source | 6,300,000Source |
| Operating Lease, Right-of-Use AssetUSD | 10,708,000Source | 14,961,000Source | 18,631,000Source | 21,762,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 716,000Source | 580,000Source | 611,000Source | 628,000Source |
| Additional Paid in CapitalUSD | 791,748,000Source | 727,156,000Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -913,695,000Source | -910,345,000Source | -753,530,000Source | -635,717,000Source |
| Stockholders' Equity Attributable to ParentUSD | -121,231,000Source | -182,609,000Source | -24,983,000Source | 85,684,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | 727,936,000Source | 720,773,000Source |
| Liabilities and EquityUSD | 325,632,000Source | 277,079,000Source | 378,269,000Source | 590,969,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 78,062,000Source | 79,526,000Source | 53,316,000Source | 136,383,000Source |
| Operating Lease, Liability, CurrentUSD | 5,797,000Source | 5,239,000Source | — | 3,888,000Source |
| Accounts Payable, CurrentUSD | 4,764,000Source | 5,905,000Source | 7,712,000Source | 5,989,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,524,000Source | 12,224,000Source | — | 21,971,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 29,388,000Source | 26,005,000Source | 31,868,000Source | 30,551,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 171,800,000Source | 90,100,000Source | 171,800,000Source | 194,900,000Source |
| Deferred Revenue, CurrentUSD | 2,473,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
| Long-term DebtUSD | 87,900,000Source | 164,939,000Source | 213,155,000Source | 315,287,000Source |
| Short-term InvestmentsUSD | 162,144,000Source | 86,732,000Source | 164,743,000Source | 183,909,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 47,417,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 964,000Source | 950,000Source | 920,000Source | 952,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,192,000Source | 10,493,000Source | 11,650,000Source | 14,072,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -116,094,000Source | -148,803,000Source | 74,726,000Source | -86,483,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 164,523,000Source | 82,217,000Source | 27,454,000Source | -127,564,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 65,000Source | 165,000Source | 426,000Source | 113,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 0Source | 11,851,000Source | 4,654,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -42,169,000Source | 62,881,000Source | -106,084,000Source | 124,248,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 6,260,000Source | -3,705,000Source | -3,904,000Source | -89,799,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | 11,009,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 35,419,000Source | 35,686,000Source | 29,923,000Source | 19,178,000Source |
| Income Taxes Paid, NetUSD | 153,000Source | 165,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 8,192,000Source | 10,493,000Source | 11,650,000Source | 14,072,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | 1,853,000Source | 1,830,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 171,800,000Source | 90,100,000Source | 171,800,000Source | 194,900,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | 237,594,000Source | — | — | — |
| Gain (Loss) on Disposition of BusinessUSD | — | — | 0Source | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | 454,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | 0Source | 4,112,000Source | — |
| General and Administrative ExpenseUSD | — | — | — | 50,668,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -4,808,000Source | -182,629,000Source | -174,920,000Source | -182,029,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 1,458,000Source | 25,814,000Source | 57,107,000Source | 229,446,000Source |
| Income Tax Expense (Benefit)USD | 2,012,000Source | 2,305,000Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | -960,000Source | 24,675,000Source | — | — |
| Investment Income, InterestUSD | 2,300,000Source | 8,400,000Source | 14,700,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -3,350,000Source | -156,815,000Source | -117,813,000Source | 47,417,000Source |
| Proceeds from Stock Options ExercisedUSD | 7,651,000Source | 547,000Source | — | — |
| Unrealized Gain (Loss) on DerivativesUSD | -136,717,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | 41,500,000Source | 49,735,000Source | 49,660,000Source | — |
| Operating Income (Loss)USD | -122,796,000Source | -169,258,000Source | -164,530,000Source | -163,389,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -2,796,000Source | — | — | -182,029,000Source |
| Income Tax Expense (Benefit)USD | 2,012,000Source | 2,305,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -3,350,000Source | -156,815,000Source | -117,813,000Source | 47,417,000Source |
| Earnings Per Share, BasicUSD per share | -0.05Source | -2.7Source | -1.88Source | 0.76Source |
| Earnings Per Share, DilutedUSD per share | -0.05Source | — | — | 0.76Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 63,510,201Source | 58,170,931Source | 62,739,227Source | 62,737,091Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | 62,737,091Source |
| Interest Expense (non-operating)USD | -960,000Source | 24,675,000Source | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 122,796,000Source | 169,258,000Source | 164,530,000Source | 163,389,000Source |
| Current Income Tax Expense (Benefit)USD | 2,012,000Source | 2,305,000Source | 0Source | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,000,000Source | 1,000,000Source | 900,000Source | 952,000Source |
| General and Administrative ExpenseUSD | — | — | — | 50,668,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -4,808,000Source | -182,629,000Source | -174,920,000Source | -182,029,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -0.08Source | -3.14Source | -2.79Source | -2.9Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -0.08Source | — | — | -2.9Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 1,458,000Source | 25,814,000Source | 57,107,000Source | 229,446,000Source |
| Interest and Other IncomeUSD | 4,096,000Source | 11,304,000Source | 16,342,000Source | 4,062,000Source |
| Interest ExpenseUSD | — | — | 30,844,000Source | 22,702,000Source |
| Investment Income, InterestUSD | 2,300,000Source | 8,400,000Source | 14,700,000Source | — |
| Research and Development ExpenseUSD | 81,296,000Source | 119,523,000Source | 114,870,000Source | 112,721,000Source |
Filing attachments
e25416_ex107.htm · 424B5 · 2025-11-14
Exhibit 107 N/A 424B5 Calculation of Filing Fee Tables Form S-3 (Form Type) Omeros Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Security Class Fee Amount Proposed Maximum Fee Rate Amount of Carry Carry Carry Filing Fee…
Read attachment ↗tm2516030d4_ex99-1.htm · 8-K · 2025-07-25
EX-99.1 5 tm2516030d4_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering SEATTLE, WA - July 25, 2025 - Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) announced that on July 24, 2025 it entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22 million of its common stock in a registered direct offering. Under the terms of the securities purchase agreement, the C…
Read attachment ↗